Site-Specific Conjugation of Cell Wall Polyrhamnose to Protein SpyAD Envisioning a Safe Universal Group A Streptococcal Vaccine.
Group A Streptococcus
Group A carbohydrate
Lancefield antigen
SpyAD
Streptococcus pyogenes
XpressCF™
bacterial infection
click chemistry
conjugate vaccine
non-natural amino acids
Journal
Infectious microbes & diseases
ISSN: 2641-5917
Titre abrégé: Infect Microbes Dis
Pays: United States
ID NLM: 9918351166506676
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
medline:
1
6
2021
pubmed:
1
6
2021
entrez:
25
10
2024
Statut:
ppublish
Résumé
Development of an effective vaccine against the leading human bacterial pathogen group A Streptococcus (GAS) is a public health priority. The species defining group A cell wall carbohydrate (GAC, Lancefield antigen) can be engineered to remove its immunodominant N-acetylglucosamine (GlcNAc) side chain, implicated in provoking autoimmune cross-reactivity in rheumatic heart disease, leaving its polyrhamnose core (GAC
Identifiants
pubmed: 39450141
doi: 10.1097/im9.0000000000000044
pmc: PMC11501091
doi:
Types de publication
Journal Article
Langues
eng
Pagination
87-100Déclaration de conflit d'intérêts
LP, LB, AB, JF, and NK are employees of Vaxcyte, Inc. Some studies at UC San Diego were supported by a sponsored research agreement with Vaxcyte, Inc. VN previously received fees as a consultant for SutroVax, Inc., a former name of Vaxcyte.